search
Back to results

EPIC European Study: Use of the FiberNet® Emboli Protection Device in Carotid Artery Stenting

Primary Purpose

Carotid Artery Stenosis

Status
Completed
Phase
Not Applicable
Locations
Germany
Study Type
Interventional
Intervention
FiberNet Embolic Protection Device
Sponsored by
Lumen Biomedical
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional treatment trial for Carotid Artery Stenosis focused on measuring Carotid artery, distal protection device

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Candidate for percutaneous stenting with target lesion located within common or internal carotid artery. Symptomatic with atherosclerotic stenosis ≥ 50% or asymptomatic with atherosclerotic stenosis ≥ 70% of the carotid artery by NASCET Criteria. Targeted vessel diameter for FiberNet placement between 1.75 mm and 7.0 mm. The investigator determines that all branch vessels distal to the target lesion and proximal to the proposed site of device deployment will be adequately protected. Exclusion Criteria: Prior stenting of ipsilateral carotid. Planned treatment of contralateral carotid within 30 days. Experienced a myocardial infarction within the last 14 days. Undergone an angioplasty or PTCA/PTA procedure within the past 48 hours. Undergone cardiac surgery within the past 60 days. Has a planned invasive surgical procedure within 30 days. Suffered a stroke within the past 14 days. Suffered a transient ischemic neurological attack (TIA) or amaurosis fugax within the past 48 hours. Total occlusion of the target vessel. Lesions within 2 cm of the ostium of the common carotid artery. A stenosis that is known to be unsuitable for stenting because of one or more of: Tortuous or calcified anatomy proximal or distal to the stenosis, Presence of visual thrombus, Pseudo occlusion (string sign). Serial lesions that requires more then one stent to cover entire lesion.

Sites / Locations

Outcomes

Primary Outcome Measures

The primary endpoint is the rate of all death and stroke within 30 days of the procedure.

Secondary Outcome Measures

All death, stroke, and myocardial infarction rates; Non-stroke neurological event rates
Technical success rates; Procedural success rates; Access site complication rates

Full Information

First Posted
March 30, 2006
Last Updated
October 20, 2008
Sponsor
Lumen Biomedical
search

1. Study Identification

Unique Protocol Identification Number
NCT00309803
Brief Title
EPIC European Study: Use of the FiberNet® Emboli Protection Device in Carotid Artery Stenting
Official Title
Evaluating the Use of the FiberNet® Embolic Protection Device in Carotid Artery Stenting: The EPIC European Study
Study Type
Interventional

2. Study Status

Record Verification Date
October 2008
Overall Recruitment Status
Completed
Study Start Date
March 2006 (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
undefined (undefined)

3. Sponsor/Collaborators

Name of the Sponsor
Lumen Biomedical

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
Multicenter, prospective, study designed to demonstrate the performance and safety of the Lumen Biomedical, Inc. FiberNet Embolic Protection System as an adjunctive device during carotid artery percutaneous intervention. The primary endpoint is the rate of all stoke and death within 30 days of the procedure.
Detailed Description
The purpose of this feasibility study is to demonstrate the performance and safety of the Lumen Biomedical, Inc. FiberNet® Embolic Protection System as an adjunctive device during carotid artery percutaneous intervention. The feasibility study will involve a maximum of 50 subjects to be enrolled using the FiberNet® during clinically indicated percutaneous intervention of the carotid artery and followed through 30 days post procedure. Subject will be enrolled in up to 5 European Investigational Sites. The study is a prospective multi-center registry with sequential enrollment of qualified subjects who consent to participate and meet all entrance criteria.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Carotid Artery Stenosis
Keywords
Carotid artery, distal protection device

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
50 (Anticipated)

8. Arms, Groups, and Interventions

Intervention Type
Device
Intervention Name(s)
FiberNet Embolic Protection Device
Primary Outcome Measure Information:
Title
The primary endpoint is the rate of all death and stroke within 30 days of the procedure.
Secondary Outcome Measure Information:
Title
All death, stroke, and myocardial infarction rates; Non-stroke neurological event rates
Title
Technical success rates; Procedural success rates; Access site complication rates

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Candidate for percutaneous stenting with target lesion located within common or internal carotid artery. Symptomatic with atherosclerotic stenosis ≥ 50% or asymptomatic with atherosclerotic stenosis ≥ 70% of the carotid artery by NASCET Criteria. Targeted vessel diameter for FiberNet placement between 1.75 mm and 7.0 mm. The investigator determines that all branch vessels distal to the target lesion and proximal to the proposed site of device deployment will be adequately protected. Exclusion Criteria: Prior stenting of ipsilateral carotid. Planned treatment of contralateral carotid within 30 days. Experienced a myocardial infarction within the last 14 days. Undergone an angioplasty or PTCA/PTA procedure within the past 48 hours. Undergone cardiac surgery within the past 60 days. Has a planned invasive surgical procedure within 30 days. Suffered a stroke within the past 14 days. Suffered a transient ischemic neurological attack (TIA) or amaurosis fugax within the past 48 hours. Total occlusion of the target vessel. Lesions within 2 cm of the ostium of the common carotid artery. A stenosis that is known to be unsuitable for stenting because of one or more of: Tortuous or calcified anatomy proximal or distal to the stenosis, Presence of visual thrombus, Pseudo occlusion (string sign). Serial lesions that requires more then one stent to cover entire lesion.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Joachim Schofer, Prof. med.
Organizational Affiliation
Andreas-Gruntzig-Haus
Official's Role
Principal Investigator
Facility Information:
City
Dortmund
Country
Germany
City
Frankfurt
Country
Germany
City
Hamburg
Country
Germany

12. IPD Sharing Statement

Learn more about this trial

EPIC European Study: Use of the FiberNet® Emboli Protection Device in Carotid Artery Stenting

We'll reach out to this number within 24 hrs